|
Dosage/Direction for Use
Intravenous Heart failure Adult: Loading dose: 750 mcg/kg by slow inj over 2-3 min (may be repeated after 30 minutes if necessary). Maintenance: 5-10 mcg/kg/min by infusion. Max cumulative dose: 10 mg/kg in 24 hr. |
|
Contraindications
Hypersensitivity.
|
|
Special Precautions
Obstructive pulmonary or aortic disease, hypertrophic cardiomyopathy; BP and heart rate monitored during drug administration; fluid and electrolyte balance should be maintained; platelet counts and liver function should be monitored; protect amp from light. Pregnancy and lactation.
|
|
Adverse Reactions
GI disturbances, nausea, vomiting, thrombocytopaenia, hypotension, chest pain, hypersensitivity, myositis, vasculitis, nail discoloration, Inj site pain, decreased tear production.
Potentially Fatal: Cardiac arrhythmia, hepatotoxicity. |
|
Overdosage
May result in severe hypotension. General supportive and symptomatic treatment, including circulatory support, should also be initiated as necessary.
|
|
Drug Interactions
Chemical interaction with precipitation occurs with amrinone and dextrose or furosemide. Thus drug mixing should be avoided.
Potentially Fatal: Concurrent usage with disopyramide may lead to severe hypotension. |
|
Action
Amrinone is a phosphodiesterase inhibitor which has vasodilating and positive inotropic properties. It causes an increase in cyclic adenosine monophosphate conc leading to greater contractile force in cardiac muscle.
Distribution: 10-22% bound to plasma proteins. Half-life after IV admin: 4-6 hr. Metabolism: Partially metabolised in liver. Excretion: 40% excreted unchanged. |
|
Storage
Intravenous: Store at 15-30°C.
|
|
CIMS Class
|
|
ATC Classification
C01CE01 - amrinone ; Belongs to the class of phosphodiesterase inhibitors. Used in the treatment of heart failure.
|
Sign Out
